MARKET

OPGN

OPGN

OpGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.960
+0.160
+8.89%
After Hours: 2.000 +0.04 +2.04% 19:59 03/05 EST
OPEN
1.870
PREV CLOSE
1.800
HIGH
2.050
LOW
1.630
VOLUME
6.16M
TURNOVER
--
52 WEEK HIGH
5.76
52 WEEK LOW
1.520
MARKET CAP
55.14M
P/E (TTM)
-0.9722
1D
5D
1M
3M
1Y
5Y
DJ OpGen Is Maintained at Buy by Alliance Global Partners
Dow Jones · 5d ago
DJ OpGen Price Target Raised to $7.00/Share From $5.65 by Alliance Global Partners
Dow Jones · 5d ago
--Analyst Actions: Alliance Global Partners Adjusts Price Target on OpGen to $7 From $5.65, Maintains Buy Rating
MT Newswires · 5d ago
SSYS, MARA, SOS and CAN among premarket gainers
ASLAN Pharmaceuticals Limited (ASLN +71% as ASLAN004 shows positive effect in atopic dermatitis.Apollo Endosurgery (APEN +47% after receiving a Breakthrough Device Designation from the USFDA for the Orbera® Intragastric Balloon.electroCore (ECOR +39% on ex...
Seekingalpha · 6d ago
Thinking about buying stock in Aslan Pharmaceuticals, electroCore, Novan, OpGen, or Salarius Pharmaceuticals?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASLN, ECOR, NOVN, OPGN, and SLRX.
PR Newswire - PRF · 6d ago
BRIEF-OpGen Wins Chinese NMPA Approval For Curetis Unyvero System
reuters.com · 6d ago
OpGen shares gain 17% on Chinese approval of Curetis Unyvero System
OpGen (OPGN) jumps 17% premarket after receiving regulatory approval of the Curetis Unyvero System as an in vitro diagnostics ((IVD)) instrument system in China. A dossier for the review and potential future
Seekingalpha · 6d ago
OpGen Announces Chinese NMPA Approval For Curetis Unyvero System
Chinese regulatory authority NMPA completes registration of Unyvero instrument system as IVD for Chinese market   Application of Unyvero cartridge for pneumonia is under review and pending NMPA
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OPGN. Analyze the recent business situations of OpGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OPGN stock price target is 5.50 with a high estimate of 7.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 675.89K
% Owned: 2.40%
Shares Outstanding: 28.13M
TypeInstitutionsShares
Increased
7
115.15K
New
11
-39.45K
Decreased
2
48.45K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
William Rhodes
President/Chief Executive Officer/Director
Oliver Schacht
Chief Financial Officer/Secretary/IR Contact Officer
Timothy Dec
Chief Operating Officer
Johannes Bacher
Chief Information Officer
Vadim Sapiro
Director
Mario Crovetto
Independent Director
R. Don Elsey
Director
Prabhavathi Fernandes
Director
Evan Jones
Independent Director
R. Donald Elsey
No Data
About OPGN
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.

Webull offers kinds of OpGen Inc stock information, including NASDAQ:OPGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPGN stock methods without spending real money on the virtual paper trading platform.